Literature DB >> 27926695

Regulation: Rewriting the regenerative rulebook.

Michael Eisenstein.   

Abstract

Year:  2016        PMID: 27926695     DOI: 10.1038/540S63a

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  3 in total

1.  Key cost drivers of pharmaceutical clinical trials in the United States.

Authors:  Aylin Sertkaya; Hui-Hsing Wong; Amber Jessup; Trinidad Beleche
Journal:  Clin Trials       Date:  2016-02-08       Impact factor: 2.486

2.  Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.

Authors:  Leigh Turner; Paul Knoepfler
Journal:  Cell Stem Cell       Date:  2016-06-30       Impact factor: 24.633

3.  Boom in unproven cell therapies intensifies regulatory debate.

Authors:  Heidi Ledford
Journal:  Nature       Date:  2016-09-08       Impact factor: 49.962

  3 in total
  1 in total

1.  Unproven Stem Cell-Based Interventions: Advancing Policy through Stakeholder Collaboration.

Authors:  Kirstin R W Matthews; Ana S Iltis
Journal:  Tex Heart Inst J       Date:  2017-06-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.